Bibliographies thématiques / Non-Alcoholic fatty liver diseases / Thèses
Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Non-Alcoholic fatty liver diseases.

Thèses sur le sujet « Non-Alcoholic fatty liver diseases »

Auteur : Grafiati
Publié le 22 juin 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleures thèses pour votre recherche sur le sujet « Non-Alcoholic fatty liver diseases ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les thèses sur diverses disciplines et organisez correctement votre bibliographie.

1

Bayard, Max, and Jim Holt. "Non-Alcoholic Fatty Liver Disease." Digital Commons @ East Tennessee State University, 2007. https://dc.etsu.edu/etsu-works/6495.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Levene, Adam Phillip. "Steatosis in non alcoholic fatty liver disease." Thesis, Imperial College London, 2012. http://hdl.handle.net/10044/1/9691.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease is the commonest cause of chronic liver disease in developed countries. The accurate assessment of steatosis is central to the diagnosis of non-alcoholic fatty liver disease. I compared the assessment of steatosis by histology, biochemical triglyceride assays, digital image analysis, with and without Oil Red-O staining, in mouse livers and human liver biopsies. In each case Oil Red-O digital image analysis was the most reliable technique for quantitating steatosis. I then investigated a potential, non-invasive technique for distinguishing steatosis from steato
Styles APA, Harvard, Vancouver, ISO, etc.
3

De, Alwis Nimantha M. W. "Mitochondrial dysfunction in non alcoholic fatty liver disease." Thesis, University of Newcastle Upon Tyne, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.493235.

Texte intégral
Résumé :
Non Alcoholic fatty Liver disease (NAFLD) is the commonest chronic liver disease worldwide and is a spectrum which includes simple fatty liver (simple steatosis), non-alcoholic steatohepatitis (NASH) and cirrhosis. Simple steatosis is a benign condition but NASH may progress to liver fibrosis and cirrhosis. Why only some develop progressive disease is not known and maybe dependant on the pathophysiology.
Styles APA, Harvard, Vancouver, ISO, etc.
4

Liu, Yang-Lin. "Genomic studies in non-alcoholic fatty liver disease." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3822.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum that spans simple steatosis, through steatohepatitis (NASH) to fibrosis and ultimately cirrhosis. NAFLD is characterised by substantial inter-patient variation in rate of progression and disease outcome: whilst up to 25% of the general population are at risk of progressive disease, only a minority experience associated liver-related morbidity. Inter-patient genetic variation and environment determine severity and progression of NAFLD. This thesis reports a series of studies examining the association of genetic variations in two g
Styles APA, Harvard, Vancouver, ISO, etc.
5

Alshaalan, Rasha. "Non-invasive diagnostic methods for non-alcoholic fatty liver disease." Thesis, McGill University, 2013. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=119567.

Texte intégral
Résumé :
Background: NAFLD is one of the most common causes of liver disease worldwide. It is a spectrum of disease characterized by macrovesicular steatosis of the liver that ranges from simple fatty liver (steatosis), to non-alcoholic steatohepatitis (NASH). NASH may eventually evolve to cirrhosis and end stage complication. Liver biopsy has long been considered the gold standard of reference to diagnose NAFLD but it is costly and invasive. Recently, non-invasive methods have been proposed. Aims and methods: The aim of this study was to investigate the accuracy of non-invasive methods including (Ultr
Styles APA, Harvard, Vancouver, ISO, etc.
6

Hallsworth, Kate. "Physical activity, exercise and non-alcoholic fatty liver disease." Thesis, University of Newcastle upon Tyne, 2012. http://hdl.handle.net/10443/1510.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of liver conditions ranging from hepatic steatosis through steatohepatitis to cirrhosis. Its prevalence has been estimated at between one-in-five and one-in-three of the adult population depending on country and diagnostic criteria used. Prevalence increases with degree of obesity, and is very common in those with Type 2 diabetes (T2DM). Rising prevalence of obesity and T2DM, particularly in younger people, will ensure that NAFLD remains a growing clinical concern for the future. Lifestyle modification, which encompasses diet, wei
Styles APA, Harvard, Vancouver, ISO, etc.
7

Scorletti, Eleonora. "Effect of omega-3 fatty acids in non-alcoholic fatty liver disease." Thesis, University of Southampton, 2017. https://eprints.soton.ac.uk/422265/.

Texte intégral
Résumé :
The first chapter (Introduction) of the thesis summarises the pathogenesis of NAFLD and its associated risk factors such as type 2 diabetes and cardiovascular disease. Moreover, it describes: a) the potential beneficial effects of long chain omega-3 fatty acid treatment [docosahexaenoic acid (DHA) plus eicosapentaenoic acid (EPA)] in NAFLD; b) the effect of genotypes patatin-like phospholipase domain-containing protein-3 (PNPLA3 I148M) and the transmembrane 6 superfamily member 2 protein (TM6SF2 E167K), on the level of DHA and EPA enrichment and end of study liver fat percentage after DHA+EPA
Styles APA, Harvard, Vancouver, ISO, etc.
8

Spanos, Christos. "Quantitative liver proteomics for biomarker discovery in non-alcoholic fatty liver disease." Thesis, University of Surrey, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.616323.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide. Given that NAFLD can progress from steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and potentially hepatocellular carcinoma, early diagnosis and accurate disease staging are primary clinical concerns. Hypothesizing that a subset of liver proteins will exhibit differential expression in NAFLD and that these proteins may represent candidate disease biomarkers; the aims of this project were to use proteomics to identify differentially expressed proteins both in an in vitro and an in vivo model of
Styles APA, Harvard, Vancouver, ISO, etc.
9

Cheng, Lik-fai, and 鄭力暉. "Non-alcoholic fatty liver disease in Asia: a systematic review." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45171117.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

MARIN, VERONICA. "Non-Alcoholic and Alcoholic Fatty Liver disease: two sides of the same coin." Doctoral thesis, Università degli Studi di Trieste, 2017. http://hdl.handle.net/11368/2908152.

Texte intégral
Résumé :
Background and aims: The booming prevalence of obesity and diabetes in young age and the increased consumption of alcohol in adolescents lead to the development of Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Liver Disease (ALD). Task 1 of this work is focused on the development of an in vivo model of pediatric NAFLD and in the study of the therapeutic properties of Silymarin. The task 2 investigated the source of MIF, a cytokine involved in the pathogenesis of ALD. Materials and Methods: NAFLD in vivo study: C57BL/6 male and female mice were exposed to HFHCD or chow diet (CTRL die
Styles APA, Harvard, Vancouver, ISO, etc.
11

Ekstedt, Mattias. "Non-Alcoholic Fatty Liver Disease : A clinical and histopathological study." Doctoral thesis, Linköpings universitet, Gastroenterologi och hepatologi, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-17220.

Texte intégral
Résumé :
Fatty liver has previously often been associated with excessive alcohol consumption. During the last two decades, the interest in fatty liver occurring in non-drinkers i.e. non-alcoholic fatty liver disease (NAFLD) has increased dramatically. Today, NAFLD is considered as the most common liver disease in the developed world. It is strongly associated with obesity, insulin resistance, and hypertension. Thus, NAFLD is considered as the hepatic manifestation of the metabolic syndrome. The spectrum of NAFLD includes: simple fatty liver without necroinflammatory activity; non-alcoholic steatohepati
Styles APA, Harvard, Vancouver, ISO, etc.
12

Ban, Linda. "Role of extracellular vesicles in non-alcoholic fatty liver disease." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20824.

Texte intégral
Résumé :
Once thought to be a benign accumulation of hepatic fat, non-alcoholic fatty liver disease (NAFLD) is now recognised as a prevalent complication of obesity with serious consequences if left untreated. This includes liver inflammation and impaired glucose metabolism, and with time may result in cirrhosis and organ failure. While basic diagnostic tools exist, such as ultrasound and serum protein markers, these are often unreliable and warrant the use of more invasive techniques such as tissue biopsy. Given most patients only become symptomatic once the disease is advanced, there is an urgent nee
Styles APA, Harvard, Vancouver, ISO, etc.
13

Qin, Minhua. "Regulation of genes in patients with non-alcoholic fatty liver disease /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18501.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Krasnoff, Joanne B. "Health-related fitness, physical activity, and non-alcoholic fatty liver disease." [Bloomington, Ind.] : Indiana University, 2007. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3274261.

Texte intégral
Résumé :
Thesis (Ph.D.)--Indiana University, School of Health, Physical Education and Recreation, 2007.<br>Source: Dissertation Abstracts International, Volume: 68-07, Section: B, page: 4315. Adviser: Janet P. Wallace. Title from dissertation home page (viewed Apr. 15, 2008).
Styles APA, Harvard, Vancouver, ISO, etc.
15

Cepero, Donates Yuneivy. "Pathogenic role of IL-15 in non-alcoholic fatty liver disease." Mémoire, Université de Sherbrooke, 2014. http://hdl.handle.net/11143/5871.

Texte intégral
Résumé :
Abstract : Pro-inflammatory cytokines play a key role in pathogenesis of obesity and non-alcoholic fatty liver disease (NAFLD). IL-15 is a pro-inflammatory cytokine, which signals through a receptor complex composed of the IL-15 receptor (IL-15R) alpha chain, the IL-2/IL-15R beta chain and the common gamma chain. The functions of IL-15 have been extensively described in immune cells but less is known about its functions in others tissues such as the liver. The aim of this thesis is to investigate the role of IL-15 in fatty liver disease. C57BL/6 wildtype (WT) and IL-15 knockout (Il15[superscr
Styles APA, Harvard, Vancouver, ISO, etc.
16

Krishnan, Smitha. "Gut Microbiota Metabolites Modulate Inflammation in Non- Alcoholic Fatty Liver Disease." Thesis, Tufts University, 2018. http://pqdtopen.proquest.com/#viewpdf?dispub=10812893.

Texte intégral
Résumé :
<p> Recent findings, including our own work, demonstrated that intestinal microbiota species produce bioactive metabolites that engage host cellular pathways. Microbiota-derived metabolites have also been detected in circulation and in the, setting up the intriguing possibility that these bacterial products could directly interact with host cellular pathways at distant sites. The study described in this abstract investigates the hypothesis that gut microbiota dysbiosis perturbs the balance of immunomodulatory microbiota metabolites, which exacerbates liver inflammation in steatosis. We utilize
Styles APA, Harvard, Vancouver, ISO, etc.
17

Alghamdi, Shareefa. "Consequences of non-alcoholic fatty liver disease on drug-induced hepatocytoxicity." Thesis, University of Surrey, 2015. http://epubs.surrey.ac.uk/808210/.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of lipid in liver. Liver is the principal organ involved in drug biotransformation. The central hypothesis of this project is that alterations in the liver environment due to lipid accumulation aggravate sensitivity of hepatocytes to toxicity of some commonly prescribed drugs (paracetamol, alcohol, phenobarbital, cisplatin or doxorubicin). The aim of this study was to investigate the effect of lipid overloading (steatosis) on drug cytotoxicity in the liver model Huh7 cell line. Hepatic steatosis was induced in Huh7
Styles APA, Harvard, Vancouver, ISO, etc.
18

Käräjämäki, A. (Aki). "Non-alcoholic fatty liver disease (NAFLD):perspectives to etiology, complications and lipid metabolism." Doctoral thesis, Oulun yliopisto, 2017. http://urn.fi/urn:isbn:9789526217376.

Texte intégral
Résumé :
Abstract Obesity, insulin resistance, type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) form a dangerous quartet which threatens human health all over the world. About 25% of adults around the world have NAFLD, which poses risks for cardiovascular and metabolic well-being and may develop into liver cirrhosis and hepatocellular carcinoma. Apart from lifestyle modification, treatment options for NAFLD are scarce. This thesis presents atrial fibrillation (AF) as a new complication of NAFLD among general population of 958 individuals aged 40-60 years participating in the OPERA st
Styles APA, Harvard, Vancouver, ISO, etc.
19

Boateng, Anthony Osei. "Hepatoprotective properties of Gentiana spp. against non-alcoholic fatty liver disease (NAFLD)." Thesis, University of Westminster, 2018. https://westminsterresearch.westminster.ac.uk/item/q4yzy/hepatoprotective-properties-of-gentiana-spp-against-non-alcoholic-fatty-liver-disease-nafld.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disease characterised by the accumulation of fat in the liver. It is estimated that 33 % of the UK population have NAFLD with 2-5 % progressing to non-alcoholic steatohepatitis (NASH). Due to a lack of an outright therapy for NAFLD, treatment has been mainly focussed on managing the conditions associated with the disease such as obesity, diabetes mellitus and hyperlipidaemia. This study aimed to investigate the means by which hepatocyte protection is conferred by Gentiana plants (Gentiana lutea, Gentiana macrophylla, Gentiana scabra and
Styles APA, Harvard, Vancouver, ISO, etc.
20

Pang, Zhenyi. "Non-alcoholic fatty liver disease : real-time PCR analysis of gene expression /." [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe.pdf.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Pugh, Christopher James Alan. "Vascular and metabolic adaption to exercise in non-alcoholic fatty liver disease." Thesis, Liverpool John Moores University, 2011. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.570720.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is characterised by the accumulation of fat in the liver and is associated with liver-related morbidity and mortality. Nevertheless, the leading cause of death in these patients is cardiovascular disease (CVD). Excess abdominal visceral adipose tissue (VAT) is frequently expressed in NAFLD and is considered a pivotal feature in the pathogenesis ofNAFLD which is predictive of CVD. Endothelial dysfunction is an early manifestation in the development of atherosclerosis and is characterised bya diminished bioavailabilty of the anti-atherogenic molecule NO,
Styles APA, Harvard, Vancouver, ISO, etc.
22

Chung, Wing Shan Rosanna. "Effects of Dietary Sphingomyelin on Non‐alcoholic Fatty Liver Disease and Atherosclerosis." Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/13652.

Texte intégral
Résumé :
Sphingomyelin (SM) is ubiquitous in human diets. The studies in this thesis investigated the effects of pure egg SM supplementation on the risks of non-alcoholic fatty liver disease (NAFLD) and atherosclerosis development in various mouse models. High fat-fed C57BL/6 mice, a model for NAFLD, was supplemented with different doses of dietary SM for various duration. The results showed that SM supplementation significantly reduced hepatomegaly, total hepatic lipids, particularly hepatic cholesterol and triglyceride, in a dose-dependent manner after 4 weeks. All of these parameters are risk facto
Styles APA, Harvard, Vancouver, ISO, etc.
23

Pesce, Paola. "Non Alcoholic Fatty Liver Disease: non invasive markers of severity and new experimental treatments." Doctoral thesis, Università degli studi di Padova, 2018. http://hdl.handle.net/11577/3422225.

Texte intégral
Résumé :
Non Alcoholic Fatty Liver Disease (NAFLD) is a worldwide increasing disease but still many questions about its evolution, the need of a screening and the availability of effective specific treatments are open. Aims of this PhD project were: 1) the evaluation of NAFLD natural history in a subgroup of NAFLD affected diabetic patients enrolled during the daily clinical activity of a splenohepatology ecoDoppler laboratory in order to identify, if present, predictive factors of “evolutive NAFLD”; 2) the experimental evaluation, in High Fat Diet (HFD) fed rats, of the potential therapeutic effect
Styles APA, Harvard, Vancouver, ISO, etc.
24

Mahady, Suzanne E. "Epidemiological studies across the spectrum of elevated liver enzymes and non-alcoholic fatty liver disease." Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17180.

Texte intégral
Résumé :
Elevations in the liver enzyme alanine transaminase (ALT), traditionally regarded as a highly specific indicator of liver injury, are now recognised as a novel marker of impaired metabolic health. Elevated ALT has a positive, linear association with the metabolic syndrome and its individual components including truncal adiposity, type 2 diabetes and dyslipidaemia. Prospective data indicates that elevated ALT predicts incident metabolic syndrome and type 2 diabetes in a dose dependent relationship, and may predict incident cardiovascular mortality, although the latter relationship appears non-l
Styles APA, Harvard, Vancouver, ISO, etc.
25

Perchet, Thibaut. "Roles of hepatic group 1 ILC during the early stages of non-alcoholic fatty liver diseases." Thesis, Sorbonne Paris Cité, 2018. http://www.theses.fr/2018USPCC314.

Texte intégral
Résumé :
Les maladies du foies non-alcoholiques (NAFLD) représentent un large spectre de pathologies qui comprennent la stéatose ou la stéatohepatite non alcoolique (NASH). Avec un nombre de patients diagnostiqué en constante augmentation, les NAFLD sont devenues un problème majeur de santé publique dans le monde. Un hypothése de « multiples hits » à été décrite pour regrouper l’ensemble des dérégulations métaboliques associées à la transition de la stéatose vers la NASH. Cette étape est critique au cours de la pathogénèse des NAFLD. En effet dans le cas où la NASH n’est pas prise en charge, elle peut
Styles APA, Harvard, Vancouver, ISO, etc.
26

Penke, Melanie. "The NAD salvage pathway during the progression of non-alcoholic fatty liver disease." Doctoral thesis, Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-194821.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is a major chronic liver disease and thus a main reason for liver-related morbidities and mortality. NAFLD covers a wide range of diseases starting with steatosis and frequently progressing to non-alcoholic steatohepatitis (NASH), which is an independent predictor for the development of the hepatocellular carcinoma (HCC). Nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme of the mammalian NAD salvage pathway, recycles nicotinamide to nicotinamide mononucleotide (NMN), which is further converted to nicotinamide adenine dinucleotide (NAD). NA
Styles APA, Harvard, Vancouver, ISO, etc.
27

Lyall, Marcus James. "TET mediated 5’hydroxymethylation in the pathogenesis of non alcoholic fatty liver disease." Thesis, University of Edinburgh, 2017. http://hdl.handle.net/1842/29524.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) now affects around one in four adults in the human population and parallels the global increase in obesity. Within the spectrum of NAFLD, simple steatosis is associated with insulin resistance and type 2 diabetes while progression to steatohepatitis (NASH) is associated with an increased risk of liver cirrhosis and all-cause mortality. The molecular pathology of NAFLD is incompletely understood, however observational studies in human cohorts suggest the regulation of DNA methylation may play a role. 5-hydroxymethylcytosine (5hmC) is a cytosine modifica
Styles APA, Harvard, Vancouver, ISO, etc.
28

Fisher, Craig. "Non-Alcoholic Fatty Liver Disease Alters the Three Stages of Hepatic Drug Management." Diss., The University of Arizona, 2008. http://hdl.handle.net/10150/195795.

Texte intégral
Résumé :
In pharmacotherapeutics, the term "correct dosing" is based on the concept that too high a systemic concentration will lead to drug toxicity, while drug levels that are too low may not produce the intended therapeutic effect. Often, the factors determining the ability of a patient to manage a given dose rely on their capacity to efficiently metabolize and eliminate drugs from the body. The liver plays a crucial role in the processing of many clinically relevant drugs via three stages of hepatic drug management. Drugs must first be taken into hepatocytes by uptake transporters. Drugs are th
Styles APA, Harvard, Vancouver, ISO, etc.
29

MITAROTONDA, DOMENICA. "Oxysterols induce mitochondrial impairment and hepatocellular toxicity in non-alcoholic fatty liver disease." Doctoral thesis, Università di Foggia, 2016. http://hdl.handle.net/11369/338834.

Texte intégral
Résumé :
Abstract: La NAFLD (Nonalcoholic fatty liver disease) è la più comune malattia epatica cronica dei paesi occidentali con un incidenza ancora maggiore dell’epatite virale C e del danno epatico causato dall’abuso di alcool. Dal punto di vista istologico la NAFLD include la steatosi semplice (nonalcoholic fatty liver, NAFL) nella sua forma iniziale, che può evolvere in steatoepatite (NASH), caratterizzata dalla presenza di infiltrato infiammatorio e/o di fibrosi, potenzialmente progressiva in cirrosi ,epatocarcinoma (HCC) ed insufficienza epatica. Sono stati identificati diversi eventi intracellu
Styles APA, Harvard, Vancouver, ISO, etc.
30

Berlanga, Bustos Alba. "Deregulation of fatty acid metabolism and cannabinoid receptors in liver of morbidly obese women with non-alcoholic fatty liver disease." Doctoral thesis, Universitat Rovira i Virgili, 2015. http://hdl.handle.net/10803/325135.

Texte intégral
Résumé :
La malaltia del fetge gras no alcohòlic (MFGNA) inclou un espectre histològic que va des de la esteatosi simple (SS) a l'esteatohepatitis no alcohòlica (EHNA), sent aquesta última freqüentment progressiva. Donat que l'acumulació hepàtica de lípids sembla ser un mecanisme crucial en la patogènesi de la MFGNA, una millor comprensió dels mecanismes subjacents que condueixen a l'acumulació inicial de lipíds hepàtics podria ser de gran interès per controlar la progressió de la malaltia. El sistema endocannabinoide (SE), mitjançant principalment els receptors cannabinoides CB1 i CB2, sembla ser que
Styles APA, Harvard, Vancouver, ISO, etc.
31

Williams, Kathryn Helen. "The Clinical Relevance Of Non-Invasive Measures Of Liver Health And Non-Alcoholic Fatty Liver Disease (NAFLD) In Diabetes Mellitus." Thesis, The University of Sydney, 2015. http://hdl.handle.net/2123/14964.

Texte intégral
Résumé :
Introduction Non-alcoholic fatty liver disease (NAFLD) is common in adults with diabetes mellitus. In addition, it tends to occur as non-alcoholic steatohepatitis (NASH) and/or with liver fibrosis more frequently than in the general population and this has important implications for morbidity and mortality. While simple steatosis due to NAFLD can be determined by non-invasive means with reasonable ease and reliability, establishing the presence and severity of NASH and liver fibrosis degree requires more sophisticated approaches, which are in need of further development. Furthermore, our under
Styles APA, Harvard, Vancouver, ISO, etc.
32

Wong, Yue-ling, and 黃愉鈴. "The role of adipocyte fatty acid binding protein in the pathogenesis of non-alcoholic fatty liver disease." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B45164873.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Gibson, Philippa S. "Characterisation of the role of vitamin D in paediatric non-alcoholic fatty liver disease." Thesis, University of Surrey, 2017. http://epubs.surrey.ac.uk/813394/.

Texte intégral
Résumé :
Previous research has suggested a role for vitamin D in non-alcoholic fatty liver disease (NAFLD) pathogenesis. Several observational studies have observed low vitamin D status (25OHD) with poorer histological findings. The principal aims of this study were to assess diet and lifestyle, 25OHD status, gene variants in vitamin D metabolism in UK children, and separately examine the effect of vitamin D in an in vitro NAFLD model. Dietary results from the case control study (n=32) indicated vitamin D intakes of paediatric patient with biopsy-proven NAFLD and ultrasound-cleared obese patients were
Styles APA, Harvard, Vancouver, ISO, etc.
34

Anderson, Emma Louise. "The prevalence and determinants of non-alcoholic fatty liver disease in childhood and adolescence." Thesis, University of Bristol, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.684360.

Texte intégral
Résumé :
USS dataset and n=3 ,059 in the blood-based outcomes dataset). For example, the odds of USS liver fat per 100 kcal increase in energy intake at age 3 years were 1.79 (95% CIL 1.14 to 2.79). Associations of absolute macronutrient intake with the liver outcomes were inconsistent, and attenuated to the null after adjustment for total energy intake. Physical activity at ages 12 and 14 years was inversely related to risk of NAFLD in adolescence (n=I,292 in the USS dataset and n=2,612 in the blood-based outcomes dataset), for example the odds of liver fat per 15 minute increase in time spent in mode
Styles APA, Harvard, Vancouver, ISO, etc.
35

KOWALIK, MARTA ANNA. "Effect of the ligands of thyroid hormone receptor on non-alcoholic fatty liver disease." Doctoral thesis, Università degli Studi di Cagliari, 2009. http://hdl.handle.net/11584/266003.

Texte intégral
Résumé :
The term non-alcoholic fatty liver disease (NAFLD) has been used as a general name for conditions ranging from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. End-stage NAFLD cirrhosis carries a substantial risk for early hepatocellular carcinoma development. Therefore, there is an increasing need for new therapeutic approaches for the treatment of this liver disease. Here, we examined the effect of the thyroid hormone triiodothyronine (T3) and the agonist of the thyroid hormone receptor β isoform (TRβ), GC-1, on fatty liver and steatohepatitis induced in rodents by a cho
Styles APA, Harvard, Vancouver, ISO, etc.
36

Kruger, F. C. "A study of non-alcoholic fatty liver disease (NAFLD) in South African patients and analysis of candidate genes in insulin resistance and fatty acid oxidation." Thesis, Stellenbosch : Stellenbosch University, 2008. http://hdl.handle.net/10019.1/1415.

Texte intégral
Résumé :
Thesis (PhD (Medicine. Internal Medicine))--Stellenbosch University, 2008.<br>Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in Western countries, extending from steatosis (FLD) to steatohepatitis (NASH). Differentiation between NASH and nonprogressive NAFLD is difficult on clinical grounds therefore a need exists to identify reliable biomarkers of disease progression. The aims of the study were 1) to describe the disease profile of NAFLD/NASH in South African patients of the Western Cape, 2) to investigate the metabolic derangements associated with
Styles APA, Harvard, Vancouver, ISO, etc.
37

Williamson, Rachel MacLeod. "Prevalence, risk factors and sequelae of non-alcoholic fatty liver disease in Type 2 diabetes." Thesis, University of Edinburgh, 2013. http://hdl.handle.net/1842/25315.

Texte intégral
Résumé :
Type 2 diabetes is an established risk factor for non-alcoholic fatty liver disease (NAFLD). Despite this, there are few data investigating NAFLD within large populations of people with Type 2 diabetes. In the initial chapters of this thesis NAFLD is defined and the pathological processes linking it to Type 2 diabetes are described. The epidemiological evidence that underpins current understanding of prevalence, risk factors and progression of the condition is reviewed in detail. Subsequent chapters describe research undertaken within the Edinburgh Type 2 Diabetes Study on the epidemiology of
Styles APA, Harvard, Vancouver, ISO, etc.
38

Mouralidarane, A. C. "The role of developmental programming in the pathogenesis of non-alcoholic fatty liver disease (NAFLD)." Thesis, University College London (University of London), 2012. http://discovery.ucl.ac.uk/1354935/.

Texte intégral
Résumé :
Obesity induced, non-alcoholic fatty liver disease (NAFLD), describes the spectrum from steatosis-to-cirrhosis. NAFLD is now the commonest cause of chronic liver disease in affluent populations. Its prevalence is increasing in tandem with rising obesity rates. However, given the exponential rise in obesity and NAFLD disease prevalence, availability of cheap energy dense foods may not alone be the sole determinant of these rising rates: maternal obesity – through developmental programming - may also be involved. A growing body of epidemiological evidence suggests that perinatal factors may cont
Styles APA, Harvard, Vancouver, ISO, etc.
39

Akie, Thomas E. "Regulation of Metabolism by Hepatic OXPHOS: A Dissertation." eScholarship@UMMS, 2015. https://escholarship.umassmed.edu/gsbs_diss/857.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent issue in the modern world, predisposing patients to serious pathology such as cirrhosis and hepatocellular carcinoma. Mitochondrial dysfunction, and in particular, diminished hepatic oxidative phosphorylation (OXPHOS) capacity, have been observed in NAFLD livers, which may participate in NAFLD pathogenesis. To examine the role of OXPHOS in NAFLD, we generated a model of enhanced hepatic OXPHOS using mice with liver-specific transgenic expression of LRPPRC, a protein which activates mitochondrial transcription and augments O
Styles APA, Harvard, Vancouver, ISO, etc.
40

Akie, Thomas E. "Regulation of Metabolism by Hepatic OXPHOS: A Dissertation." eScholarship@UMMS, 2010. http://escholarship.umassmed.edu/gsbs_diss/857.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent issue in the modern world, predisposing patients to serious pathology such as cirrhosis and hepatocellular carcinoma. Mitochondrial dysfunction, and in particular, diminished hepatic oxidative phosphorylation (OXPHOS) capacity, have been observed in NAFLD livers, which may participate in NAFLD pathogenesis. To examine the role of OXPHOS in NAFLD, we generated a model of enhanced hepatic OXPHOS using mice with liver-specific transgenic expression of LRPPRC, a protein which activates mitochondrial transcription and augments O
Styles APA, Harvard, Vancouver, ISO, etc.
41

Fisher, Leslie Reginald. "Evaluation of high-throughput methodology for multi-gene screening in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)." Thesis, Stellenbosch : Stellenbosch University, 2011. http://hdl.handle.net/10019.1/17896.

Texte intégral
Résumé :
Thesis (MScMedSc)--Stellenbosch University, 2011.<br>ENGLISH ABSTRACT: Non-Alcoholic Fatty Liver Disease (NAFLD) is the most prevalent chronic liver disease in Western countries and is considered the hepatic manifestation of the Metabolic Syndrome (MetS). Its heterogeneous nature ranges from hepatic steatosis through steatohepatitis to advanced fibrosis and cirrhosis where the ingestion of significant amounts of alcohol has been excluded. The disease profile of NAFLD and its necro-inflammatory subset Nonalcoholic Steatohepatitis (NASH) were described in the parent study, which provided a clini
Styles APA, Harvard, Vancouver, ISO, etc.
42

Zou, Xiantong. "The role of 11β-hydroxysteroid dehydrogenase type 1 in liver fibrosis and inflammation in non-alcoholic fatty liver disease". Thesis, University of Edinburgh, 2014. http://hdl.handle.net/1842/18748.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is a worldwide health problem which includes steatosis (triglyceride accumulation alone), non-alcoholic steatohepatitis (NASH, with liver inflammation), fibrosis, cirrhosis and hepatocellular carcinoma. Liver fibrosis, which is a reversible response, is the final phase of most chronic liver disease and is characterized by accumulation of extracellular matrix (ECM) from activated hepatic stellate cells (HSCs). Glucocorticoids (GCs) regulate many aspects of metabolism involved in NAFLD. Also, GCs limit HSC activation in vitro. Tissue GC levels are regula
Styles APA, Harvard, Vancouver, ISO, etc.
43

Jarrar, Mohammed Hussein. "Comparative profiling of circulatory levels of adipokines and cytokines in patients with various types of non alcoholic fatty liver disease." Fairfax, VA : George Mason University, 2007. http://hdl.handle.net/1920/2927.

Texte intégral
Résumé :
Thesis (Ph. D.)--George Mason University, 2007.<br>Title from PDF t.p. (viewed Jan. 18, 2008). Thesis director: Ancha Baranova Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biosciences. Vita: p. 213 Includes bibliographical references (p. 188-212). Also available in print.
Styles APA, Harvard, Vancouver, ISO, etc.
44

Jolin-Rodrigue, Gabriel. "Effects of Imidacloprid in the Development of Non-Alcoholic Fatty Liver Disease and the Effects of Exercise Training." Thesis, Université d'Ottawa / University of Ottawa, 2019. http://hdl.handle.net/10393/38900.

Texte intégral
Résumé :
The non-alcoholic fatty liver disease (NAFLD) is the most common liver pathology in developed countries with an estimated prevalence of 20 to 30% in the American population. A typically benign and asymptomatic pathology, NAFLD is characterized by hepatic steatosis and abnormal levels of hepatic enzymes stemming from an increase in circulating free fatty acids originating from white adipose tissue lipolysis, an increased de novo lipogenesis, reduced fatty acid oxidation and decreased hepatic triglycerides secretion, all within an insulin resistance context. NAFLD has the potential to progress t
Styles APA, Harvard, Vancouver, ISO, etc.
45

Lin, Hui-Ting, and 林惠婷. "The Extracts of Mulberry Leaves inhibits Non-Alcoholic Fatty Liver Disease and Alcoholic Fatty Liver Disease." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/52558303651182285354.

Texte intégral
Résumé :
碩士<br>中山醫學大學<br>生化暨生物科技研究所<br>102<br>Non-alcoholic fatty liver disease (NAFLD), a leading cause of liver damage, comprises of a spectrum of liver abnormalities including the early fat deposition in the liver (hepatic steatosis) and advanced nonalcoholic steatohepatitis (NASH). In addition, alcoholic liver disease (ALD) also lead to similar liver syndrome with NASH.In previous studies, mulberry leaves had been demonstrated to possess anti-oxidantant promoting effects. In this study, we have examined the effect of water extracts of mulberry leaves (MLE) on HFD-induced hepatic steatosis in rats.
Styles APA, Harvard, Vancouver, ISO, etc.
46

Van, Rooyen Derrick Michael. "Cholesterol as a mediator of hepatic injury in non-alcoholic steatohepatitis." Phd thesis, 2012. http://hdl.handle.net/1885/150765.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent. 20-30% of patients with NAFLD progress to non-alcoholic steatohepatitis (NASH), characterised by steatosis, ballooning degeneration of hepatocytes, inflammation and fibrosis, but the cause(s) of this transition remains unclear. Foz/foz (Alms1 mutant) mice develop hyperphagia and obesity-related NAFLD. High fat (HF)-feeding induces NASH transition by 12 weeks, and fibrosis by 24 weeks. The aims of this research were to investigate the cause and effect of hepatic cholesterol dysregulation in foz/foz mice, its pathogenic significance
Styles APA, Harvard, Vancouver, ISO, etc.
47

Magalhães, Nuno Manuel Queiroz Pimenta de. "Body composition in non-alcoholic fatty liver disease patients." Doctoral thesis, 2014. http://hdl.handle.net/10400.5/7450.

Texte intégral
Résumé :
Doutoramento em Motricidade Humana, na especialidade de Actividade Física e Saúde<br>The present thesis includes five original studies focusing on body composition (BC) in non-alcoholic fatty liver disease (NAFLD) patients, mainly in a clinical perspective, directed to clinical practice. The first study of this thesis aimed at analyzing the relation between body fat (BF) content and distribution, as assessed by dual energy x-ray absorptiometry (DXA), and cardiac autonomic control, more specifically with heart rate recovery after a maximal exercise test, which is an indirect clinical marker of
Styles APA, Harvard, Vancouver, ISO, etc.
48

"Non-invasive evaluation of non-alcoholic fatty liver disease using biochemical and genetic markers." 2013. http://library.cuhk.edu.hk/record=b5884459.

Texte intégral
Résumé :
Shen, Jiayun.<br>Thesis (Ph.D.)--Chinese University of Hong Kong, 2013.<br>Includes bibliographical references (leaves 166-199).<br>Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web.<br>Abstract also in Chinese.
Styles APA, Harvard, Vancouver, ISO, etc.
49

Islam, Tawhidul. "Targeting liver cell metabolism and function in non-alcoholic fatty liver disease." Doctoral thesis, 2021. http://hdl.handle.net/10451/50381.

Texte intégral
Résumé :
Non-alcoholic fatty liver disease (NAFLD) comprises a series of liver lesions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and is a major cause of chronic liver disease that may progress to cirrhosis and hepatocellular carcinoma. Despite the risk factors related with the metabolic syndrome, the mechanisms of disease are not entirely known. Further, several promising molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Therefore, a better understanding of NAFLD pathogenesis and str
Styles APA, Harvard, Vancouver, ISO, etc.
50

Fox, Ryan. "Vitamin D to reduce liver fibrosis in non-alcoholic fatty liver disease." Thesis, 2017. https://hdl.handle.net/2144/26591.

Texte intégral
Résumé :
BACKGROUND: As the prevalence of metabolic risk factors in the American population has increased over time, so too has the diagnoses of non-alcoholic fatty liver disease (NAFLD). Within this spectrum of disease lies the potential for silent progression towards cirrhosis, leaving the patient with few options for treatment. Currently, the standard of care remains counseling on diet and exercise with the goal of reversing disease progression by addressing the underlying risk factors. LITERATURE REVIEW: Recent studies have shown that a correlation exists between low levels of serum 25-hydroxy
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie